Home
Data
Calendar
Blog
| 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock Value | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | NA | 0.21 | NA | NA | |
| Weighted Average Number Of Diluted Shares Outstanding | 0.03 | 0.03 | 0.03 | NA | 26.47 | 26.43 | 0.03 | NA | 26.34 | 26.32 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Weighted Average Number Of Shares Outstanding Basic | 0.03 | 0.03 | 0.03 | NA | 26.47 | 26.43 | 0.03 | NA | 26.34 | 26.32 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Weighted Average Number Of Share Outstanding Basic And Diluted | NA | NA | NA | NA | NA | NA | 26.38 | 26.36 | 26.34 | 26.32 | 26.24 | 24.89 | 22.94 | 18.79 | 14.52 | 14.51 | 13.20 | 10.41 | 10.10 | NA | 10.09 | 10.06 | |
| Earnings Per Share Basic | -0.61 | -1.98 | 1.91 | 4.44 | -1.33 | -0.82 | -1.94 | -1.47 | -2.05 | -2.07 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Earnings Per Share Diluted | -0.61 | -1.98 | 1.87 | 4.44 | -1.33 | -0.82 | -1.94 | -1.47 | -2.05 | -2.07 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Earnings Per Share Basic And Diluted | NA | NA | NA | NA | NA | NA | -1.94 | -1.47 | -2.05 | -2.07 | -2.15 | -1.25 | -0.92 | -0.55 | -0.67 | -0.76 | -0.56 | -0.07 | -0.68 | -0.09 | -0.42 | -0.99 |
| 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue From Contract With Customer Excluding Assessed Tax | 45.14 | 10.52 | 80.28 | 160.29 | 13.37 | 27.09 | 5.24 | 5.79 | 2.44 | 2.00 | 2.13 | 2.24 | 2.33 | 2.32 | 2.65 | 2.97 | 3.32 | 10.15 | 4.35 | 7.58 | 3.42 | 2.39 | |
| Revenues | 45.14 | 10.52 | 80.28 | 160.29 | 13.37 | 27.09 | 5.24 | 5.79 | 2.44 | 2.00 | 2.13 | 2.24 | 2.33 | 2.32 | 2.65 | 2.97 | 3.32 | 10.15 | 4.35 | 7.58 | 3.42 | 2.39 | |
| Operating Expenses | 64.45 | 65.89 | 65.53 | 38.84 | 50.18 | 49.18 | 55.62 | 43.44 | 56.26 | 55.72 | 59.79 | 33.32 | 23.27 | 12.36 | 12.11 | 13.79 | 10.93 | 10.72 | 10.86 | 8.29 | 7.78 | 12.46 | |
| Research And Development Expense | 51.08 | 52.67 | 51.77 | 26.98 | 37.69 | 38.19 | 44.89 | 32.63 | 45.40 | 45.68 | 50.05 | 24.29 | 17.70 | 7.94 | 7.92 | 11.99 | 7.05 | 7.27 | 7.32 | 4.85 | 3.97 | 4.22 | |
| General And Administrative Expense | 13.38 | 13.22 | 13.76 | 11.86 | 12.49 | 10.99 | 10.73 | 10.81 | 10.86 | 10.04 | 9.74 | 9.03 | 5.57 | 4.42 | 4.19 | 1.79 | 3.88 | 3.46 | 3.53 | 3.44 | 3.81 | 8.23 | |
| Operating Income Loss | -19.31 | -55.37 | 14.76 | 121.45 | -36.81 | -22.09 | -50.38 | -37.65 | -53.82 | -53.72 | -57.67 | -31.08 | -20.94 | -10.04 | -9.46 | -10.82 | -7.62 | -0.57 | -6.51 | -0.71 | -4.36 | -10.07 | |
| Interest Expense Long Term Debt | NA | NA | NA | -1.20 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.20 | 0.20 | 0.20 | 0.20 | 0.30 | 0.30 | 0.20 | 0.20 | 0.20 | NA | NA | NA | |
| Interest Paid Net | 0.00 | 0.00 | 2.10 | 0.23 | 0.23 | 0.19 | 0.17 | 0.51 | 0.00 | 0.00 | 0.17 | 0.58 | -0.01 | -0.05 | 0.23 | 0.18 | 0.17 | 0.17 | 0.17 | NA | NA | NA | |
| Gains Losses On Extinguishment Of Debt | 0.00 | 0.00 | 33.95 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Allocated Share Based Compensation Expense | 9.27 | 8.38 | 8.18 | -24.05 | 9.44 | 7.27 | 7.37 | 7.52 | 6.87 | 7.54 | 6.99 | 2.83 | 1.99 | 1.10 | 0.85 | 0.80 | 0.38 | 0.40 | 0.40 | 0.51 | 0.59 | 0.14 | |
| Income Tax Expense Benefit | 0.89 | 0.58 | 0.10 | NA | NA | NA | 0.10 | NA | NA | NA | NA | NA | 0.00 | 0.00 | NA | NA | NA | NA | NA | NA | NA | NA | |
| Net Income Loss | -16.22 | -52.55 | 50.75 | 117.35 | -35.27 | -21.56 | -51.17 | -38.66 | -54.08 | -54.58 | -56.35 | -31.10 | -21.00 | -10.26 | -9.78 | -10.99 | -7.43 | -0.69 | -6.88 | -1.01 | -4.25 | -9.95 | |
| Comprehensive Income Net Of Tax | -16.22 | -52.55 | 50.75 | 117.35 | -35.27 | -21.56 | -51.17 | -38.66 | -54.08 | -54.58 | -56.35 | -31.10 | -21.00 | -10.26 | -9.78 | -10.99 | -7.43 | -0.69 | -6.88 | -1.01 | -4.25 | -9.94 |
| 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | 457.65 | 430.65 | 470.86 | 450.39 | 293.63 | 337.01 | 341.99 | 392.81 | 434.54 | 448.81 | 481.47 | 476.46 | 322.52 | 149.94 | 72.10 | 82.14 | 87.22 | 70.94 | NA | 44.20 | NA | NA | |
| Liabilities | 177.59 | 145.47 | 141.62 | 180.07 | 147.96 | 166.30 | 157.24 | 164.60 | 175.41 | 143.16 | 128.86 | 79.90 | 60.89 | 56.51 | 55.12 | 56.35 | 51.32 | 49.32 | NA | 30.56 | NA | NA | |
| Liabilities And Stockholders Equity | 457.65 | 430.65 | 470.86 | 450.39 | 293.63 | 337.01 | 341.99 | 392.81 | 434.54 | 448.81 | 481.47 | 476.46 | 322.52 | 149.94 | 72.10 | 82.14 | 87.22 | 70.94 | NA | 44.20 | NA | NA | |
| Stockholders Equity | 280.06 | 285.18 | 329.25 | 270.31 | 145.67 | 170.72 | 184.75 | 228.21 | 259.13 | 305.65 | 352.61 | 396.55 | 261.63 | 93.42 | 16.98 | 25.79 | 35.90 | 21.62 | 6.35 | 13.64 | 14.15 | 17.80 |
| 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets Current | 393.27 | 385.24 | 424.56 | 403.33 | 246.68 | 291.50 | 327.00 | 378.96 | 420.97 | 438.04 | 470.00 | 467.79 | 314.10 | 142.00 | 63.76 | 74.29 | 79.41 | 63.34 | NA | 41.83 | NA | NA | |
| Cash And Cash Equivalents At Carrying Value | 311.92 | 323.47 | 327.94 | 391.88 | 237.68 | 283.49 | 319.68 | 370.49 | 413.88 | 433.57 | 466.84 | 462.89 | 307.02 | 136.11 | 59.47 | 71.35 | 74.17 | 55.84 | 31.22 | 36.71 | 30.33 | 29.32 | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 369.05 | 380.60 | 330.05 | 393.98 | 239.76 | 285.57 | 321.75 | 372.57 | 415.95 | 433.68 | 466.95 | 463.00 | 307.13 | 136.22 | 59.58 | 71.46 | 74.28 | 55.95 | 31.33 | 36.82 | 30.44 | 29.43 | |
| Accounts Receivable Net Current | 38.22 | 2.80 | 92.48 | 2.76 | 2.04 | 2.25 | 3.69 | 3.37 | 2.02 | 2.16 | 2.01 | 2.12 | 2.45 | 2.83 | 2.35 | 2.18 | 2.62 | 5.82 | NA | 4.48 | NA | NA |
| 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Property Plant And Equipment Gross | 20.64 | 19.82 | 19.00 | 18.20 | 16.58 | 13.77 | 12.01 | 9.90 | 8.79 | 7.06 | 6.80 | 6.44 | 6.25 | 5.18 | 4.93 | 4.53 | 4.10 | 3.83 | NA | 3.47 | NA | NA | |
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 7.92 | 7.10 | 6.36 | 5.78 | 5.23 | 4.82 | 4.48 | 4.26 | 3.95 | 3.66 | 3.37 | 3.06 | 2.79 | 2.58 | 2.36 | 2.18 | 2.03 | 1.85 | NA | 1.50 | NA | NA | |
| Property Plant And Equipment Net | 12.71 | 12.72 | 12.63 | 12.41 | 11.35 | 8.95 | 7.53 | 5.64 | 4.84 | 3.41 | 3.43 | 3.38 | 3.45 | 2.61 | 2.57 | 2.35 | 2.07 | 1.99 | NA | 1.98 | NA | NA |
| 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities Current | 87.68 | 90.34 | 90.13 | 126.98 | 75.85 | 92.74 | 107.31 | 99.54 | 118.24 | 70.77 | 53.33 | 49.52 | 28.01 | 23.05 | 21.65 | 21.32 | 21.69 | 16.41 | NA | 12.58 | NA | NA | |
| Long Term Debt Current | NA | NA | NA | 60.66 | 27.70 | 27.02 | 24.26 | 22.47 | 18.48 | 5.00 | 3.12 | 1.25 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Accounts Payable Current | 18.36 | 13.62 | 19.34 | 7.45 | 17.96 | 5.76 | 10.01 | 10.06 | 8.27 | 10.08 | 5.60 | 10.77 | 6.48 | 4.39 | 3.78 | 5.79 | 4.01 | 3.19 | NA | 2.40 | NA | NA | |
| Taxes Payable Current | 0.48 | NA | 1.40 | 1.29 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Accrued Liabilities Current | 28.55 | 28.76 | 32.29 | 30.23 | 25.53 | 33.61 | 19.97 | 23.52 | 52.36 | 42.61 | 29.80 | 20.64 | 15.84 | 11.88 | 9.78 | 7.13 | 6.68 | 3.50 | NA | 3.91 | NA | NA |
| 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long Term Debt | NA | NA | NA | NA | 13.30 | 15.30 | 15.30 | 15.30 | 15.30 | 15.30 | 15.30 | 15.30 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Long Term Debt Noncurrent | 20.00 | NA | NA | NA | 32.04 | 35.76 | 39.23 | 40.63 | 42.34 | 56.31 | 58.15 | 13.85 | 15.08 | 15.06 | 15.03 | 14.99 | 10.02 | 9.98 | NA | 9.91 | NA | NA | |
| Other Liabilities Noncurrent | 0.98 | 1.29 | 1.73 | 2.80 | 3.68 | NA | NA | NA | 1.39 | 0.88 | 0.36 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Operating Lease Liability Noncurrent | 27.02 | 28.11 | 29.19 | 30.22 | 31.22 | 32.20 | 4.06 | 4.50 | 4.93 | 5.36 | 5.71 | 4.03 | 4.16 | 4.39 | 4.63 | 4.85 | NA | NA | NA | NA | NA | NA |
| 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | 280.06 | 285.18 | 329.25 | 270.31 | 145.67 | 170.72 | 184.75 | 228.21 | 259.13 | 305.65 | 352.61 | 396.55 | 261.63 | 93.42 | 16.98 | 25.79 | 35.90 | 21.62 | 6.35 | 13.64 | 14.15 | 17.80 | |
| Common Stock Value | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | NA | 0.21 | NA | NA | |
| Additional Paid In Capital | 636.19 | 625.09 | 616.61 | 608.43 | 601.13 | 590.91 | 583.38 | 575.67 | 567.93 | 560.37 | 552.74 | 540.34 | 374.32 | 185.11 | 98.41 | 97.44 | 96.56 | 74.85 | NA | 58.30 | NA | NA | |
| Retained Earnings Accumulated Deficit | -356.16 | -339.94 | -287.39 | -338.14 | -455.49 | -420.22 | -398.66 | -347.49 | -308.83 | -254.74 | -200.16 | -143.82 | -112.71 | -91.71 | -81.44 | -71.67 | -60.68 | -53.25 | NA | -44.87 | NA | NA | |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 9.27 | 8.38 | 8.18 | NA | 9.44 | 7.27 | 7.37 | 7.52 | 6.87 | 7.54 | 6.99 | 2.83 | 1.99 | 1.10 | 0.85 | 0.80 | 0.38 | 0.40 | 0.40 | 0.51 | 0.59 | 0.14 |
| 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -32.41 | 50.81 | -35.87 | 160.26 | -42.41 | -36.82 | -49.04 | -42.50 | -16.65 | -32.94 | -42.95 | -6.63 | -15.88 | -8.49 | -11.86 | -7.54 | -2.84 | 9.34 | -5.41 | -5.76 | -6.79 | NA | |
| Net Cash Provided By Used In Investing Activities | -0.98 | -0.35 | -0.69 | -3.81 | -2.19 | 0.38 | -2.11 | -1.12 | -1.77 | -0.40 | -0.12 | -0.70 | -0.43 | -0.47 | -0.14 | -0.32 | -0.16 | -0.27 | -0.08 | 2.27 | 7.82 | NA | |
| Net Cash Provided By Used In Financing Activities | 21.84 | 0.09 | -27.36 | -2.23 | -1.22 | 0.26 | 0.34 | 0.23 | 0.69 | 0.08 | 47.01 | 163.20 | 187.22 | 85.60 | 0.12 | 5.03 | 21.33 | NA | NA | 9.87 | -0.02 | NA |
| 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -32.41 | 50.81 | -35.87 | 160.26 | -42.41 | -36.82 | -49.04 | -42.50 | -16.65 | -32.94 | -42.95 | -6.63 | -15.88 | -8.49 | -11.86 | -7.54 | -2.84 | 9.34 | -5.41 | -5.76 | -6.79 | NA | |
| Net Income Loss | -16.22 | -52.55 | 50.75 | 117.35 | -35.27 | -21.56 | -51.17 | -38.66 | -54.08 | -54.58 | -56.35 | -31.10 | -21.00 | -10.26 | -9.78 | -10.99 | -7.43 | -0.69 | -6.88 | -1.01 | -4.25 | -9.95 | |
| Increase Decrease In Accounts Receivable | 35.42 | -89.68 | 89.72 | 0.72 | -0.20 | -1.44 | 0.32 | 1.35 | -0.15 | 0.16 | -0.12 | -0.32 | -0.38 | 0.48 | 0.17 | -0.45 | -3.19 | 1.36 | -0.02 | 3.36 | -0.25 | NA | |
| Increase Decrease In Accounts Payable | 4.90 | -6.20 | 11.79 | -8.45 | 9.76 | -4.38 | -0.04 | 1.80 | -1.78 | 4.62 | -5.42 | 4.80 | 1.46 | 0.83 | -2.28 | 1.67 | 0.72 | -0.81 | 1.58 | -0.36 | 0.10 | NA | |
| Share Based Compensation | 9.27 | 8.38 | 8.18 | 6.53 | 9.44 | 7.27 | 7.37 | 7.52 | 6.87 | 7.54 | 6.99 | 2.83 | 1.99 | 1.10 | 0.85 | 0.80 | 0.38 | 0.40 | 0.40 | 0.51 | 0.59 | NA |
| 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Investing Activities | -0.98 | -0.35 | -0.69 | -3.81 | -2.19 | 0.38 | -2.11 | -1.12 | -1.77 | -0.40 | -0.12 | -0.70 | -0.43 | -0.47 | -0.14 | -0.32 | -0.16 | -0.27 | -0.08 | 2.27 | 7.82 | NA | |
| Payments To Acquire Property Plant And Equipment | 0.98 | 0.35 | 0.69 | 3.81 | 2.19 | -0.38 | 2.11 | 1.12 | 1.77 | 0.40 | 0.12 | 0.70 | 0.43 | 0.47 | 0.14 | 0.32 | 0.16 | 0.27 | 0.08 | 0.23 | 0.25 | NA |
| 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Financing Activities | 21.84 | 0.09 | -27.36 | -2.23 | -1.22 | 0.26 | 0.34 | 0.23 | 0.69 | 0.08 | 47.01 | 163.20 | 187.22 | 85.60 | 0.12 | 5.03 | 21.33 | NA | NA | 9.87 | -0.02 | NA |
| 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 45.14 | 10.52 | 80.28 | 160.29 | 13.37 | 27.09 | 5.24 | 5.79 | 2.44 | 2.00 | 2.13 | 2.24 | 2.33 | 2.32 | 2.65 | 2.97 | 3.32 | 10.15 | 4.35 | 7.58 | 3.42 | 2.39 | |
| Cure Vac A G | NA | NA | NA | NA | 0.23 | 0.23 | 0.22 | 0.31 | 0.24 | 0.25 | 0.23 | 0.22 | 0.24 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Israel Ministry Of Health | NA | NA | NA | NA | 0.00 | 12.50 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Janssen | NA | NA | NA | NA | 0.93 | 0.53 | 1.13 | 0.90 | 0.64 | 0.77 | 0.82 | 0.49 | 0.88 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Other | NA | NA | NA | NA | 0.04 | 0.16 | 0.10 | -0.10 | 0.03 | 0.06 | 0.15 | 0.02 | 0.30 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Ultragenyx | NA | NA | NA | NA | 0.93 | 0.96 | 0.93 | 0.92 | 0.93 | 0.93 | 0.93 | 1.25 | 0.91 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Vinbiocare | NA | NA | NA | NA | 11.24 | 12.72 | 2.86 | 3.76 | 0.60 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Biomedical Advanced Research And Development Authority, Grant | 1.76 | 0.95 | 0.56 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Csl Seqirus, Collaboration Revenue | 43.43 | 7.61 | 78.22 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Israel Ministry Of Health, Collaboration Revenue | NA | NA | NA | NA | NA | 12.50 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Janssen, Collaboration Revenue | 0.00 | 0.17 | 0.49 | 6.61 | 0.93 | 0.53 | 1.13 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Other, Collaboration Revenue | -0.06 | 1.79 | 1.02 | -3.38 | 1.20 | 1.34 | 1.25 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Vinbiocare, Collaboration Revenue | NA | NA | NA | -2.24 | 11.24 | 12.72 | 2.86 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Collaboration Revenue | 43.38 | 9.56 | 79.73 | 160.05 | 13.37 | 27.09 | 5.24 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Grant | 1.76 | 0.95 | 0.56 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Revenue From Contract With Customer Excluding Assessed Tax | 45.14 | 10.52 | 80.28 | 160.29 | 13.37 | 27.09 | 5.24 | 5.79 | 2.44 | 2.00 | 2.13 | 2.24 | 2.33 | 2.32 | 2.65 | 2.97 | 3.32 | 10.15 | 4.35 | 7.58 | 3.42 | 2.39 | |
| Cure Vac A G | NA | NA | NA | NA | 0.23 | 0.23 | 0.22 | 0.31 | 0.24 | 0.25 | 0.23 | 0.22 | 0.24 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Israel Ministry Of Health | NA | NA | NA | NA | 0.00 | 12.50 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Janssen | NA | NA | NA | NA | 0.93 | 0.53 | 1.13 | 0.90 | 0.64 | 0.77 | 0.82 | 0.49 | 0.88 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Other | NA | NA | NA | NA | 0.04 | 0.16 | 0.10 | -0.10 | 0.03 | 0.06 | 0.15 | 0.02 | 0.30 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Ultragenyx | NA | NA | NA | NA | 0.93 | 0.96 | 0.93 | 0.92 | 0.93 | 0.93 | 0.93 | 1.25 | 0.91 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Vinbiocare | NA | NA | NA | NA | 11.24 | 12.72 | 2.86 | 3.76 | 0.60 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Biomedical Advanced Research And Development Authority, Grant | 1.76 | 0.95 | 0.56 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Csl Seqirus, Collaboration Revenue | 43.43 | 7.61 | 78.22 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Israel Ministry Of Health, Collaboration Revenue | NA | NA | NA | NA | NA | 12.50 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Janssen, Collaboration Revenue | 0.00 | 0.17 | 0.49 | 6.61 | 0.93 | 0.53 | 1.13 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Other, Collaboration Revenue | -0.06 | 1.79 | 1.02 | -3.38 | 1.20 | 1.34 | 1.25 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Vinbiocare, Collaboration Revenue | NA | NA | NA | -2.24 | 11.24 | 12.72 | 2.86 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Collaboration Revenue | 43.38 | 9.56 | 79.73 | 160.05 | 13.37 | 27.09 | 5.24 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Grant | 1.76 | 0.95 | 0.56 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
